Plain-English translation of NCT04919629 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing (APL-2), a newer medication, either alone or combined with two other cancer drugs called and . The study focuses on patients with ovarian, fallopian tube, or peritoneal cancer that has returned after prior treatment and who are experiencing troublesome fluid buildup in the abdomen or chest. Researchers want to see if this medication can reduce the fluid buildup and slow cancer growth while being safe enough for long-term use.
Recurrent ovarian cancer with fluid buildup (called malignant effusion) is difficult to manage and significantly impacts quality of life. Current treatments don't work well for everyone, so researchers are testing whether this new treatment can better control the fluid and help patients live longer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of three treatment combinations, given every 3 weeks for up to 7 cycles (about 5 months), though you may continue one of the medications longer if it is helping. Each cycle involves IV infusions given at the clinic and self-administered injections at home twice a week. You'll have regular blood tests, imaging scans, and possibly tumor biopsies to check how well the treatment is working and monitor for side effects. Throughout the study, you'll also complete questionnaires about your symptoms, quality of life, and any fluid buildup you experience.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States